



Breast Cancer: Mechanisms of Development and Progression and Novel Approaches to Clinical Management

Guest Editors:

Dr. Armen Parsyan

General Surgeon and Breast
Surgical Oncologist, Clinician-
Scientist Assistant Professor,
Departments of Surgery and
Oncology, St Joseph's Health
Care and London Health
Sciences Centre, London
Regional Cancer Program,
Schulich School of Medicine &
Dentistry, Western University
London, ON

Dr. Vasudeva Bhat

Anatomy and Cell Biology,
University of Western Ontario,
London, ON, Canada

Deadline for manuscript
submissions:

closed (31 August 2021)

Message from the Guest Editors

Dear Colleagues,

Breast cancer is a major cause of morbidity and mortality among women worldwide. A significant progress has been made in our understanding of the biology of breast cancer that has served as a foundation for the development of clinically effective diagnostic, prevention, and treatment strategies. While in early-stage breast cancer, excellent outcomes are observed, the metastatic, recurrent, and drug-resistant disease still confers an unacceptably poor prognosis. Certain subtypes of this malignancy, such as its most aggressive triple-negative subtype, lack predictive and treatment biomarkers, which contributes to the relatively poor oncologic outcomes. The significant heterogeneity of breast cancer mandates a nuanced understanding and management that requires further research efforts. This issue discusses mechanisms of breast cancer development and progression, as well as presents recent preclinical studies on novel approaches in treatment of this condition.

Dr. Armen Parsyan

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)